Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

We recently published a list of 10 Best Wide Moat Stocks to Invest In. In this article, we are going to take a look at where ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

If investors are looking at the Mid Cap Growth fund category, make sure to pass over Eventide Gilead Fund N (ETGLX). ETGLX possesses a Zacks Mutual Fund Rank of 5 (Strong Sell), which is based on ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $97.2 which represents a slight increase of $0.25 or 0.26% from the prior close of $96.95. The stock opened at $96.73 and ...

Bullish option flow detected in Gilead (GILD) with 14,401 calls trading, 4x expected, and implied vol increasing over 4 points to 27.50%.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Reba Harris was the fearless leader of the Gilead House, a 27-bed women’s shelter which offers support services, classes and ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...

Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as ...